Samiha Jaddaoui, Hanaa Bencharef, Sara Addakiri, Hind Dehbi, Amal Tazzite, Mouna Lamchahab, Bouchra Oukkache
{"title":"[Prognostic value of residual disease detection in acute myeloid leukemia with normal karyotype and negative FLT3-ITD].","authors":"Samiha Jaddaoui, Hanaa Bencharef, Sara Addakiri, Hind Dehbi, Amal Tazzite, Mouna Lamchahab, Bouchra Oukkache","doi":"10.1684/abc.2023.1798","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Complete remission (CR) in patients with acute myeloid leukemia (AML) is still morphologicaly defined, thus corresponding to a wide range of tumor burden.</p><p><strong>Objectives: </strong>we aimed to evaluate the residual disease (MRD) status in patients with AML, as well as perform a molecular analysis of the FLT3/ITD gene in patients with normal karyotype.</p><p><strong>Material and methods: </strong>adult patients with AML, diagnosed according to the WHO 2016 criteria, were included. MRD was detected using flow cytometric techniques after induction treatment resulting in CR.</p><p><strong>Results: </strong>thirty patients met our inclusion criteria. 83 % of them had an intermediate risk status, 67 % of which (20/30) having a normal karyotype. MRD and leukemic stem cell (LSC) positivity in this group was predominant with considerable decrease in benign progenitor count. The relapse-free survival (RFS) in the group of MRD negative patients with normal cytogenetics and non-mutated FLT3 gene was better than the RFS in all of our patients studied.</p><p><strong>Conclusion: </strong>MRD and LSC are powerful prognostic factors for relapse. They should be routinely integrated to guide better management of AML.</p>","PeriodicalId":7892,"journal":{"name":"Annales de biologie clinique","volume":"81 2","pages":"136-144"},"PeriodicalIF":0.4000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/abc.2023.1798","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Complete remission (CR) in patients with acute myeloid leukemia (AML) is still morphologicaly defined, thus corresponding to a wide range of tumor burden.
Objectives: we aimed to evaluate the residual disease (MRD) status in patients with AML, as well as perform a molecular analysis of the FLT3/ITD gene in patients with normal karyotype.
Material and methods: adult patients with AML, diagnosed according to the WHO 2016 criteria, were included. MRD was detected using flow cytometric techniques after induction treatment resulting in CR.
Results: thirty patients met our inclusion criteria. 83 % of them had an intermediate risk status, 67 % of which (20/30) having a normal karyotype. MRD and leukemic stem cell (LSC) positivity in this group was predominant with considerable decrease in benign progenitor count. The relapse-free survival (RFS) in the group of MRD negative patients with normal cytogenetics and non-mutated FLT3 gene was better than the RFS in all of our patients studied.
Conclusion: MRD and LSC are powerful prognostic factors for relapse. They should be routinely integrated to guide better management of AML.
期刊介绍：
Multidisciplinary information with direct relevance to everyday practice
Annales de Biologie Clinique, the official journal of the French Society of Clinical Biology (SFBC), supports biologists in areas including continuing education, laboratory accreditation and technique validation.
With original articles, abstracts and accounts of everyday practice, the journal provides details of advances in knowledge, techniques and equipment, as well as a forum for discussion open to the entire community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
